PMID- 31625408
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20210406
IS  - 2169-141X (Electronic)
IS  - 2169-1401 (Linking)
VI  - 47
IP  - 1
DP  - 2019 Dec
TI  - Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs 
      targeted.
PG  - 4066-4088
LID - 10.1080/21691401.2019.1677680 [doi]
AB  - Ovarian cancer is the second most common gynaecological malignancy. It usually 
      occurs in women older than 50 years, and because 75% of cases are diagnosed at 
      stage III or IV it is associated with poor diagnosis. Despite the 
      chemosensitivity of intraperitoneal chemotherapy, the majority of patients is 
      relapsed and eventually dies. In addition to the challenge of early detection, 
      its treatment presents several challenges like the route of administration, 
      resistance to therapy with recurrence and specific targeting of cancer to reduce 
      cytotoxicity and side effects. In ovarian cancer therapy, nanocarriers help 
      overcome problems of poor aqueous solubility of chemotherapeutic drugs and 
      enhance their delivery to the tumour sites either by passive or active targeting, 
      and thus reducing adverse side effects to the healthy tissues. Moreover, the 
      bioavailability to the tumour site is increased by the enhanced permeability and 
      retention (EPR) mechanism. The present review aims to describe the current 
      conventional treatment with special reference to passively and actively targeted 
      drug delivery systems (DDSs) towards specific receptors designed against ovarian 
      cancer to overcome the drawbacks of conventional delivery. Conclusively, targeted 
      nanocarriers would optimise the intra-tumour distribution, followed by drug 
      delivery into the intracellular compartment. These features may contribute to 
      greater therapeutic effect.
FAU - Gupta, Swati
AU  - Gupta S
AD  - Amity Institute of Pharmacy, Amity University Uttar Pradesh , Noida , India.
FAU - Pathak, Yashwant
AU  - Pathak Y
AD  - College of Pharmacy, University of South Florida Health , Tampa , FL , USA.
AD  - Faculty of Pharmacy, University of Airlangga , Surabaya , Indonesia.
FAU - Gupta, Manish K
AU  - Gupta MK
AD  - TERI-Deakin Nanobiotechnology Centre, The Energy and Resources Institute (TERI), 
      Gual Pahari, TERI Gram , Gurugram , India.
FAU - Vyas, Suresh P
AU  - Vyas SP
AD  - Department of Pharmaceutical Sciences, Dr H.S. Gour University , Sagar , India.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PT  - Review
PL  - England
TA  - Artif Cells Nanomed Biotechnol
JT  - Artificial cells, nanomedicine, and biotechnology
JID - 101594777
SB  - IM
RIN - Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):291. PMID: 33821716
MH  - Drug Delivery Systems/*methods
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Nanomedicine/*methods
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/drug therapy/epidemiology/pathology/*therapy
OTO - NOTNLM
OT  - Drug carriers
OT  - chemotherapy
OT  - nanotechnology
OT  - plant extracts
OT  - receptors
OT  - targeting
EDAT- 2019/10/19 06:00
MHDA- 2020/03/24 06:00
CRDT- 2019/10/19 06:00
PHST- 2019/10/19 06:00 [entrez]
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
AID - 10.1080/21691401.2019.1677680 [doi]
PST - ppublish
SO  - Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4066-4088. doi: 
      10.1080/21691401.2019.1677680.